← Leaderboards
Dmitri Kireev
Univ Of North Carolina Chapel Hill
$921,810
Attributed
$2,186,380
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $825.3K · FY2020–23$1M$750K$500K$250K$0
'20
'21
'22
'23
Funding mix
By agency
NIH$2,186,380 · 2
By mechanism
R01$2,186,380 · 2
Top collaborators
- Nathaniel A. Hathaway4 shared
- Douglas K Graham2 shared
- Xiaodong Wang2 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Nathaniel A. Hathaway$4,359,744
- Xiaodong Wang$2,479,253
- Brian D Strahl$12,633,933
- Michael Benjamin Major$9,815,030
- Charles M Perou$46,508,459
Others in their field
Other Emerging Leaders on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Yunda Huang · Fred Hutchinson Cancer Center$73,602,469
- James Dale Berry · Brigham And Women'S Hospital$25,538,716
- Ionut Bebu · George Washington University$18,816,779
- Barbara Halina Braffett · George Washington University$18,816,779
- Gary Fanger · Rise Therapeutics, Llc$17,847,765
Research focus
MediatingCancer TherapyResponseSignal TransductionEventIn VivoMalignant NeoplasmsProteinsCellsStructureBaseDoxycyclineArchitectureCalibrationBiologyData SetEmbryonic Stem CellComputational PlatformChromosome Conformation CaptureCell Culture TechniquesBiochemical ReactionComplexComplementComputerized Tools
Grant awards (6)
Computational and experimental insights into the structure and dynamics of heterochromatin$245,560
R01 · FY2023 · GM · contact PI
Computational and experimental insights into the structure and dynamics of heterochromatin$304,179
R01 · FY2022 · GM · contact PI
MERTK/AXL dual inhibitors provide novel treatment for cancer by targeting tumor cells and activating anti-tumor immunity$507,204
R01 · FY2021 · CA
Computational and experimental insights into the structure and dynamics of heterochromatin$304,179
R01 · FY2021 · GM · contact PI
MERTK/AXL dual inhibitors provide novel treatment for cancer by targeting tumor cells and activating anti-tumor immunity$521,079
R01 · FY2020 · CA
Computational and experimental insights into the structure and dynamics of heterochromatin$304,179
R01 · FY2020 · GM · contact PI